Daily Digest
Monday, May 4, 2026
Regulatory Watch
Peptide Weekly Digest: April 27 to May 3, 2026
This week was a major one for the peptide world. The biggest themes were tighter FDA scrutiny of compounded GLP-1 drugs, strong late-stage obesity data from Boehringer Ingelheim and Zealand Pharma, new Phase 3 momentum for an amylin analog, and continued expansion of peptide-based platforms outside of weight loss.
1. FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list
The most important regulatory story this week came from the FDA. On April 30, the agency proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying it did not identify a clinical need for outsourcing facilities to compound these drugs from bulk substances.
That matters because 503B outsourcing facilities are the larger-scale compounders that can manufacture compounded drugs without patient-specific prescriptions under certain conditions. If finalized, the proposal would further limit large-scale production of compounded versions of GLP-1 drugs such as semaglutide and tirzepatide, especially now that branded supply has stabilized.
The FDA opened the proposal for public comment through June 29, 2026. Reuters reported that Novo Nordisk and Eli Lilly welcomed the move, while telehealth and compounding businesses that rely on lower-cost compounded GLP-1s could face more pressure.
Why it matters: This is another sign that the window for broad, large-scale compounded GLP-1 sales is narrowing. For peptide vendors, telehealth platforms, and comparison sites, the distinction between FDA-approved GLP-1 products, 503A patient-specific compounding, and 503B bulk compounding is becoming more important.
Sources:
- FDA: FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List
- Reuters: U.S. FDA proposes curbs on mass compounding of Novo, Lilly's weight-loss drugs
2. Boehringer and Zealand reported strong Phase 3 data for survodutide
Boehringer Ingelheim and Zealand Pharma announced positive topline Phase 3 results for survodutide, a glucagon/GLP-1 receptor dual agonist being developed for obesity and overweight.
In the SYNCHRONIZE-1 trial, adults with obesity or overweight but without type 2 diabetes lost up to an average of 16.6% of body weight after 76 weeks, compared with 3.2% in the placebo arm. The trial also met a co-primary endpoint showing that up to 85.1% of treated adults achieved at least 5% body-weight reduction, versus 38.8% on placebo.
The companies emphasized that weight reduction appeared to be driven mostly by fat loss, with lean mass contributing only a small proportion of total weight lost. Full results are expected to be presented at the American Diabetes Association’s 2026 Scientific Sessions in June.
Why it matters: Survodutide is part of the next wave of incretin-based obesity drugs that go beyond single GLP-1 activity. Its glucagon component may help differentiate it by targeting liver fat and broader metabolic health, though the full safety and tolerability profile will matter a lot once detailed data are released.
Sources:
- Zealand Pharma: Survodutide achieved 16.6% weight loss in Phase 3 trial
- Reuters: Boehringer-Zealand drug leads to 16.6% weight loss in late-stage trial
- BioPharma Dive: Boehringer dual-acting obesity shot hits mark in Phase 3 trial
3. Zealand and Roche advanced petrelintide, an amylin analog, toward Phase 3
Zealand Pharma also had another major obesity-related update this week. On April 29, Zealand and Roche announced formal endorsement to advance petrelintide into Phase 3 trials for chronic weight management. The Phase 3 program is planned to begin in the second half of 2026.
Petrelintide is a long-acting amylin analog intended for once-weekly subcutaneous administration. Amylin is a hormone involved in satiety and appetite regulation, and the pathway has become one of the most closely watched alternatives or complements to GLP-1 therapy.
Why it matters: Amylin analogs are emerging as a serious obesity-drug category. They may become useful as standalone treatments, combination partners, or options for patients who do not tolerate GLP-1-based therapies well. Roche’s commitment to move petrelintide into Phase 3 keeps the obesity pipeline competitive beyond Novo Nordisk and Eli Lilly.
Sources:
- Zealand Pharma: Zealand Pharma and Roche to advance petrelintide to Phase 3 trials
- Zealand Pharma: Petrelintide pipeline page
- BioPharm International: Zealand Pharma and Roche advance petrelintide to Phase 3
4. Novo Nordisk prepared to launch an Ozempic pill in the U.S.
Novo Nordisk announced that Ozempic tablets would become available in the U.S. starting Monday, May 4. The company described the product as an updated formulation and branding of oral semaglutide for adults with type 2 diabetes.
Novo said the tablet doses will be 1.5 mg, 4 mg, and 9 mg. The company positioned the product as an oral peptide GLP-1 medication for adults with type 2 diabetes, including cardiovascular risk-reduction indications in eligible patients.
Why it matters: Oral peptide delivery has historically been difficult because peptides are often degraded in the digestive system. A broader commercial push behind oral semaglutide reinforces how important non-injectable peptide delivery has become, especially for diabetes and obesity markets.
Sources:
5. Viking Therapeutics reported continued progress for VK2735
Viking Therapeutics reported its first-quarter 2026 results and gave an update on VK2735, its dual GLP-1/GIP receptor agonist for obesity and metabolic disorders.
The company said both VANQUISH Phase 3 studies of subcutaneous VK2735 are fully enrolled. Viking also said planned Phase 3 studies for an oral tablet formulation are expected to begin later in 2026. The company is positioning VK2735 as a potential oral and subcutaneous dual GLP-1/GIP co-agonist for obesity.
Why it matters: The obesity-drug race is no longer just about one or two products. Viking’s progress shows how crowded the next-generation incretin space is becoming, with companies competing on efficacy, tolerability, dosing convenience, oral formulations, and manufacturing scalability.
Sources:
- Viking Therapeutics: Q1 2026 financial results and corporate update
- PRNewswire: Viking Therapeutics Q1 2026 update
6. New enzyme research could improve future peptide drug design
ScienceDaily highlighted University of Utah research on PapB, an enzyme that can reshape therapeutic peptides into ring-like structures through macrocyclization. Cyclic peptides can be more stable, last longer in the body, and interact more effectively with biological targets.
The coverage framed PapB as potentially useful for improving peptide drugs such as GLP-1 therapies, including semaglutide-like molecules. The broader idea is that enzymatic modification could make peptide therapeutics more durable and easier to optimize.
Why it matters: This is not a near-term commercial drug launch, but it points to where peptide drug discovery is going. Better peptide engineering could eventually improve stability, dosing frequency, target binding, and delivery across categories such as metabolic disease, gastrointestinal disease, oncology, and antimicrobial therapy.
Sources:
- ScienceDaily: Scientists discover enzyme that could supercharge Ozempic
- University of Utah: U chemists discover enzyme that could help build next-generation GLP-1 drugs
- ACS: Leader-Independent C-Terminal Modification by a Radical S-Adenosyl-L-Methionine Enzyme Enables Macrocyclic GLP-1-Like Peptides
7. Bicycle Therapeutics advanced its bicyclic peptide oncology pipeline
Bicycle Therapeutics reported recent business progress and Q1 2026 results, including updates on nuzefatide pevedotin, a Bicycle Drug Conjugate targeting EphA2.
The company said it began enrolling a Phase 2 trial in March 2026 for adults with recurrent pancreatic ductal adenocarcinoma, and the first patient was dosed in April. Bicycle also highlighted human imaging data for an EphA2-targeting Bicycle Imaging Agent presented at AACR 2026.
Why it matters: Peptides are not just about GLP-1s and weight loss. Bicycle’s platform uses constrained synthetic peptides to target tumors, deliver payloads, and potentially support imaging or radiopharmaceutical applications. This is one of the more interesting examples of peptide-like structures being used in oncology drug delivery.
Sources:
- Bicycle Therapeutics: Recent business progress and Q1 2026 results
- Business Wire: Bicycle Therapeutics Q1 2026 update
8. vVARDIS raised growth capital for peptide-containing dental technology
vVARDIS announced a strategic minority investment from Apollo-managed funds and said the deal established the company as a billion-dollar-plus privately owned healthcare company.
The investment is intended to support global expansion of Curodont, a non-invasive peptide-containing dental technology designed to treat early tooth decay without drilling. The company said Curodont has been used to treat about 3 million teeth and is present in nearly 20% of U.S. general dental practices.
Why it matters: This is a good reminder that peptide applications extend beyond injectable drugs. Peptide-containing materials and formulations are also being used in dentistry, orthopedics, wound care, diagnostics, and regenerative medicine.
Sources:
9. Biomea reported C-peptide preservation data in type 1 diabetes
Biomea Fusion announced 52-week results from its Phase 2 COVALENT-112 trial evaluating icovamenib in type 1 diabetes. This is not a peptide therapy story in the same sense as GLP-1s or peptide conjugates, but it is relevant because C-peptide is an important biomarker of insulin production and beta-cell function.
The company reported a 52% increase from baseline in mean C-peptide AUC at Week 12 in a small subgroup of patients diagnosed within 0 to 3 years and treated with 200 mg icovamenib. Biomea also said C-peptide levels were largely preserved through Week 52 following only 12 weeks of dosing.
Why it matters: C-peptide is often used to understand remaining beta-cell function in diabetes. If longer studies confirm the signal, therapies that preserve or restore C-peptide could become meaningful in type 1 diabetes research. However, this update is early and based on small patient subsets, so it should be interpreted cautiously.
Sources:
10. Computational peptide design continued to gain visibility
Decoy Therapeutics announced presentations at two peptide therapeutics conferences in Boston during the week of April 27. The company is developing Designable Multi-Antivirals using its peptide conjugate platform, IMP³ACT.
One of the presentations focused on computational peptide design, including the shift from natural ligand reengineering toward de novo design of peptide therapeutics. The company also highlighted a partnership with Quantori to deploy an AI-driven peptide design and molecular simulation platform.
Why it matters: AI-assisted peptide design is becoming a visible part of the peptide therapeutics ecosystem. For early-stage discovery, the promise is faster design cycles, better target matching, and more systematic optimization before candidates move into expensive wet-lab and clinical work.
Sources:
Bottom line
This week showed how broad the peptide market has become. GLP-1s and obesity drugs still dominate attention, especially with the FDA’s proposed 503B restrictions and new Phase 3 obesity data from Boehringer and Zealand. But the week also featured meaningful activity in amylin analogs, oral peptide delivery, cyclic peptide engineering, oncology drug conjugates, dental applications, and computational peptide design.
For the peptide industry, the clearest trend is separation. Regulated pharmaceutical peptide development is accelerating, while compounded and gray-market peptide activity is facing more scrutiny. For buyers, researchers, and vendors, the next few months could bring more clarity on which peptide categories remain broadly accessible and which become increasingly restricted.